Overview. Over the past three years, using its in-silico discovery platform for predictive drug discovery (i.e. computer models and algorithms), Compugen (NASDAQ:CGEN) has developed a hugely compelling drug Pipeline across several clinical areas with high unmet needs. Compugen's Pipeline includes more than thirty drug candidates in areas with significant interest to large Pharma including cancer immunotherapy, immunology, and its most recently announced discoveries, antibody drug conjugates (ADC).
Despite the company's recent rapid success, and albeit strong stock price performance - up 125% in the past 7 months - its small market cap ($465 million) suggests it still remains well-below the radar of most investors. We think this could change in a very meaningful way as the market comes...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|